{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 33,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a dark sidebar for product specs and a white main area for trial design and results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/19",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "PCN-101 Phase 2a study design flow from screening to treatment to follow-up",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81cd0fb8-9ee0-486a-a7aa-7c20cdf6a5c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale... 1. Unless otherwise indicated... 2. Leal et al... 3. NCT05414422",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1674a733-17c3-40e8-85a5-211a81d929ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.32,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "list",
      "text": "OWNERSHIP 58.9% | PRODUCT Subcutaneous R-ketamine | PHARMACOLOGY Glutamatergic modulator | FEATURES Rapid-acting, non-dissociative | INDICATIONS TRD | STATUS Phase 2a results Jan 2023 | IP Issued methods | HIGHLIGHT Third party study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "752683fa-0f2c-4595-bb33-e65de0f3aa8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.36,
        "y": 0.6
      },
      "kind": "list",
      "text": "1. Study did not meet primary endpoint. 2. Mean change on MADRS was -15.3 vs -13.7. 3. Encouraging signals of efficacy. 4. Generally well-tolerated.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e84f8c2e-5b3a-452f-8e01-ac711d778772",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c9709d1-fc24-433d-8410-5b3822c34df4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.06
      },
      "kind": "title",
      "text": "We’ve completed a Phase 2a study for PCN-101 and are evaluating next steps for the program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "821d516b-082d-4b5a-951a-3dfedd909af5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "4dea6c78-cd97-4bea-9037-41aac3ba7d86",
      "evidence": "The slide presents data from a Phase 2a study, including results and next steps, telling a story about the program's progress.",
      "confidence": 0.7
    },
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1acb65bc-d6f8-4acb-95ea-07876fd870fd",
      "evidence": "The slide title is 'We’ve completed a Phase 2a study for PCN-101 and are evaluating next steps for the program' and type is 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}